Baicalin has been used in China to treat inflammation-related diseases, such as inflammation-induced acute kidney injury (AKI). However, the specific mechanism of baicalin remains unclear. To observe the protective effects of baicalin on lipopolysaccharide (LPS)-induced inflammatory injury of renal tubular epithelial cells (HK-2 cells) and to explore its protective mechanism. LPS (1 mg/L) was used to induce an HK-2 cell inflammatory injury model in vitro. The cells were divided into seven groups: the normal control group, LPS-induced group, LPS plus 5 mu mol/L baicalin treatment group, LPS plus 15 mu mol/L baicalin treatment group, LPS plus 25 mu mol/L baicalin treatment group, LPS plus 50 mu mol/L baicalin treatment group, and LPS plus 75 mu mol/L baicalin treatment group. 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay was employed for detecting the relative survival rate of HK-2 cells. Enzyme-linked immunosorbent assay was used for detecting the levels of inflammatory factors, including interleukin-6 (IL-6), IL-1 beta, and tumor necrosis factor-alpha (TNF-alpha). Moreover, the expression of inducible nitric oxide synthase (iNOS); cyclooxygenase-2 (COX-2); nuclear factor kB65 (NF-kappa B65); phosphorylated NF-kappa B inhibitory protein-alpha (p-IKB-alpha); NF-kappa B inhibitory protein (I kappa B); human thioredoxin interacting protein (TXNIP); and human NACHT, LRR, and PYD domain-containing protein 3 (NLRP3) were determined by Western blot analysis. The expression levels of NLRP3 and TXNIP mRNA and miR-223-3p were determined by RT-PCR. Results found that the relative survival rate of HK-2 cells treated with different baicalin concentrations was significantly increased (P<0.05) and the levels of the inflammatory factors IL-6, IL-1 beta, and TNF-alpha were significantly decreased (P<0.05) compared with those of the LPS-induced group. The expression levels of the inflammatory proteins inducible nitric oxide synthase and cyclooxygenase-2 and the genes expressions of TXNIP and NLRP3 were significantly decreased in the cells (P<0.05), while the expression level of miR-223-3p was significantly increased (P<0.05). These changes were induced in a dose-dependent manner. The results suggest that baicalin significantly inhibited the expression of inflammation-related proteins and alleviated LPS-induced inflammatory injury in HK-2 cells. The mechanism may be associated with the inhibition of activation of the TXNIP/NLRP3 inflammatory pathway, which might be mediated by increased expression of miR-223-3p. Thus, NLRP3 is a regulatory target of miR-223-3p.
基金:
Yunnan Applied Basic Research Project-Union Foundation [2017FE468(-032)]
语种:
外文
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版:
大类|4 区医学
小类|4 区内分泌学与代谢4 区免疫学4 区医学:研究与实验4 区生理学
最新[2023]版:
大类|4 区医学
小类|4 区内分泌学与代谢4 区免疫学4 区医学:研究与实验4 区生理学
JCR分区:
出版当年[2020]版:
Q4PHYSIOLOGYQ4MEDICINE, RESEARCH & EXPERIMENTALQ4IMMUNOLOGYQ4ENDOCRINOLOGY & METABOLISM
最新[2023]版:
Q4ENDOCRINOLOGY & METABOLISMQ4IMMUNOLOGYQ4MEDICINE, RESEARCH & EXPERIMENTALQ4PHYSIOLOGY
第一作者机构:[1]Kunming Med Univ, Affiliated Hosp 6, Dept Nephrol, 21 Nieer Rd, Hongta Dist 653100, Yuxi, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Kunming Med Univ, Affiliated Hosp 6, Dept Nephrol, 21 Nieer Rd, Hongta Dist 653100, Yuxi, Peoples R China
推荐引用方式(GB/T 7714):
Sun Y.,Liu M-W,Zhao Y-H,et al.BAICALIN ATTENUATES LIPOPOLYSACCHARIDE-INDUCED RENAL TUBULAR EPITHELIAL CELL INJURY BY INHIBITING THE TXNIP/NLRP3 SIGNALLING PATHWAY VIA INCREASING miR-223-3p EXPRESSION[J].JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS.2020,34(1):69-82.
APA:
Sun, Y.,Liu, M-W,Zhao, Y-H,Lu, Y-X,Wang, Y-A&Tong, C-W.(2020).BAICALIN ATTENUATES LIPOPOLYSACCHARIDE-INDUCED RENAL TUBULAR EPITHELIAL CELL INJURY BY INHIBITING THE TXNIP/NLRP3 SIGNALLING PATHWAY VIA INCREASING miR-223-3p EXPRESSION.JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS,34,(1)
MLA:
Sun, Y.,et al."BAICALIN ATTENUATES LIPOPOLYSACCHARIDE-INDUCED RENAL TUBULAR EPITHELIAL CELL INJURY BY INHIBITING THE TXNIP/NLRP3 SIGNALLING PATHWAY VIA INCREASING miR-223-3p EXPRESSION".JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS 34..1(2020):69-82